22 januari 2018: Bron: EPMA J. 2015; 6: 25. Published online 2015 Dec 21.

Wanneer vrouwen met intraepithelial neoplasia (CIN) I–II (poliepen), dus met hoog risico op het krijgen van baarmoederhalskanker dagelijks 200 mg per dag DIM - diindolylmethane nemen naast de gebruikeljke medicijnen dan hebben zij weinig tot geen kans op het krijgen van baarmoederhalskanker want binnen 90 tot 180 dagen verdwenen de CIN i en II afwijkingen) volledig. In vergelijking als de DIM dosis 100 mg. per dag was of een placebo waren de CIN afwijkingen verdwenen bij respectievelijk 90 procent en 61 procent voor placebo.

Het gebruik van DIM - diindolylmethaan in de vorm van intravaginale zetpillen kan dus effectief zijn bij patiënten met CIN I-II en gaat niet gepaard met klinisch significante bijwerkingen, aldus de onderzoekers. Deze aanpak zou een betere optie kunnen zijn voor jonge vrouwen met CIN I-II, omdat het hun eventuele kinderwensen beschermd en in tact laat. Aldus de onderzoekers. Het is een kleine fase IIA studie maar wel placebo dubbelblind gerandomiseerd dus een kwalitatief goede studie.

DIM 100 mg capsules zijn overall verkrijgbaar maar doe het aub in overleg met een complementair arts.

Uit het studierapport:

The efficacy of active drug treatment (100 and 200 mg/day) in both treatment groups was significantly higher in comparison with the placebo group, according to the primary efficacy end point (proportion of patients with complete CIN regression after 90–180 days of the study drug treatment).

DIM grafiek bij baarmoederhalskanker preventie

Het is bekend dat baarmoederhalskanker voornamelijk wordt veroorzaakt door het HPV virus dat meestal begint met intraepithelial neoplasia (CIN) afwijkingen (stadium I, II en III)

Uit het studierapport:

CIN I resolves spontaneously in 50–60 % of cases within 3 years. At the same time, intraepithelial neoplasia develops within 2 years in 15–30 % of women infected with high-risk HPV [6], while about 10–20 % of CIN III cases transform into invasive cervical cancer [7].

In het volledige studierapport: Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention staat een gedetailleerde beschrijving van de aanpak, maar ook van waarom de onderozkers denken dat DIM zo goed werkt en op welke specifieke genen dit invloed heeft. Maar is voor mij te medisch technisch en is wellciht beter dit met een arts te bespreken. Maar arts-bioloog drs. Engelbert Valstar is over deze studie wel enthousiast.

Hier het abstract van de studie met referentielijst.

the use of diindolylmethane in the form of intravaginal suppositories can be effective in patients with CIN I–II and is not accompanied by clinically significant side effects. This approach could be a better option for young women with CIN I–II as it takes in attention their reproductive plans.

. 2015; 6: 25.

Published online 2015 Dec 21. doi: 10.1186/s13167-015-0048-9

PMCID: PMC4685602

Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention

Levon Ashrafian, Gennady Sukhikh, Vsevolod Kiselev, Mikhail Paltsev, Vadim Drukh, Igor Kuznetsov, Ekaterina Muyzhnek, Inna Apolikhina, and Evgeniya Andrianova

Abstract

BACKGROUND:

The article presents the results of a clinical trial on the efficacy and safety of a novel pharmaceutical composition in the form of vaginal suppositories containing diindolylmethane in the course of cervical intraepithelial neoplasia (CIN) I-II conservative treatment. It offers an attractive drug therapy for more personalized prevention of cervical cancer.

METHODS:

A total of 78 women of reproductive age were included. This was a multicenter, randomized, placebo-controlled, double-blind, parallel-group trial with efficacy determined by histological evaluation of cervical biopsies. The efficacy of active drug treatment (100 and 200 mg/day) in both treatment groups was significantly higher in comparison with the placebo group, according to the primary efficacy end point (proportion of patients with complete CIN regression after 90-180 days of the study drug treatment).

RESULTS:

The efficacies were 100.0 % (confidence interval (CI) 95 %: 82.35-100.00 %), 90.5 % (CI 95 %: 69.62-98.83 %), and 61.1 % (CI 95 %: 35.75-82.70 %), for the high dose, low does, and placebo, respectively. Adverse events in the placebo group were reported in 22 % of patients (CI 95 %: 7.5-43.7 %); in the first treatment group (100 mg/day), adverse events were reported in 40.0 % of patients (CI 95 %: 21.1-61.3 %); in the second treatment group (200 mg/day), adverse events were reported in 42.0 % of patients (CI 95 %: 22.1-63.4 %). The differences in side effects between treatment groups treated with the active drug and placebo were statistically significant. No serious adverse events were reported in any of the groups.

CONCLUSIONS:

Thus, the use of diindolylmethane in the form of intravaginal suppositories can be effective in patients with CIN I-II and is not accompanied by clinically significant side effects. This approach could be a better option for young women with CIN I-II as it takes in attention their reproductive plans.

TRIAL REGISTRATION:

ID: ChiCTR-INR-15007497 (2 December 2015).

References

1. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118(8):2048–55. doi: 10.1002/ijc.21604. [PubMed] [Cross Ref]

2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: IARC CancerBase, 11. Lyon, France: International Agency for Research on Cancer; 2013. GLOBOCAN 2012 v1.0. 2012.

3. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. doi: 10.1128/CMR.16.1.1-17.2003. [PMC free article] [PubMed] [Cross Ref]

4. Schmitz M, Driesch C, Jansen L. Non-random integration of the HPV genome in cervical cancer. PLoS One. 2012;7(6):e39632. doi: 10.1371/journal.pone.0039632. [PMC free article] [PubMed] [Cross Ref]

5. Munoz N, Kato I, Bosch FX, Eluf-Neto J, De Sanjosé S, Ascunce N, et al. Risk factor for HPV DNA detection in middle-aged women. Sex Transm Dis. 1996;23(6):504–10. doi: 10.1097/00007435-199611000-00012. [PubMed] [Cross Ref]

6. Nawroth F, Sudik R, Wolf C, Quaas J. Is there an increase of serum antisperm antibodies following surgery in the cervical transformation zone for cervical intraepithelial neoplasia (CIN)? Zentralbl Gynakol. 2000;122(3):165–68. [PubMed]

7. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12(2):186–92. doi: 10.1097/00004347-199304000-00018. [PubMed] [Cross Ref]

8. Lu Q, Ma D, Zhao S. DNA methylation changes in cervical cancers. Methods Mol Biol. 2012;863:155–76. doi: 10.1007/978-1-61779-612-8_9. [PubMed] [Cross Ref]

9. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH, et al. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer. 2006;119(8):1908–14. doi: 10.1002/ijc.22060. [PubMed] [Cross Ref]

10. Saavedra KP, Brebi PM, Roa JC. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 2012;4(1):13. doi: 10.1186/1868-7083-4-13. [PMC free article] [PubMed] [Cross Ref]

11. Au Yeung CL, Tsang WP, Tsang TY, Co NN, Yau PL, Kwok TT. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol Rep. 2010;24(6):1599–1604. [PubMed]

12. Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F. Viral oncoproteins target the DNA methyltransferases. Oncogene. 2007;26(11):1650–55. doi: 10.1038/sj.onc.1209950. [PMC free article] [PubMed] [Cross Ref]

13. Longworth MS, Wilson R, Laimins LA. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J. 2005;24(10):1821–30. doi: 10.1038/sj.emboj.7600651. [PMC free article] [PubMed] [Cross Ref]

14. Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, Osborne MP, et al. Estrogen metabolite ratios and risk assessment of hormone-related cancers. Assay validation and prediction of cervical cancer risk. Ann N Y Acad Sci. 1995;768:312–316. doi: 10.1111/j.1749-6632.1995.tb12149.x. [PubMed] [Cross Ref]

15. Chung S, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 2008;68(23):9928–9934. doi: 10.1158/0008-5472.CAN-08-2051. [PMC free article] [PubMed] [Cross Ref]

16. Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. BMJ. 2014;349:g6192. doi: 10.1136/bmj.g6192. [PMC free article] [PubMed] [Cross Ref]

17. Forsmo S, Hansen MH, Jacobsen BK, Oian P. Pregnancy outcome after laser surgery for cervical intraepithelial neoplasia. Acta Obstet Gynecol Scand. 1996;75(2):139–143. doi: 10.3109/00016349609033306. [PubMed] [Cross Ref]

18. Yliskoski M, Syrjänen K, Syrjänen S, Saarikoski S, Nethersell A. Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecol Oncol. 1991;43(1):55–60. doi: 10.1016/0090-8258(91)90009-T. [PubMed] [Cross Ref]

19. Balk JL. Indole-3-carbinol for cancer prevention. Altern Med Alert. 2000;3:105–107.

20. Bell MC, Crowley-Nowick P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, Howell P, et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol. 2000;78(2):123–129. doi: 10.1006/gyno.2000.5847. [PubMed] [Cross Ref]

21. Lord RS, Bongiovanni B, Bralley JA. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern Med Rev. 2002;7(2):112–129. [PubMed]

22. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161–7. doi: 10.1207/s15327914nc5002_5. [PubMed] [Cross Ref]

23. Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Bradlow HL. Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2957–64. doi: 10.1158/1055-9965.EPI-09-0698. [PMC free article] [PubMed] [Cross Ref]

24. Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Raucci L, et al. Results from a dose response study using 3,3′-diindolylmethane in the K14-HPV16 transgenic mouse model: cervical histology. Cancer Prev Res (Phila) 2011;4(6):890–896. doi: 10.1158/1940-6207.CAPR-10-0369. [PMC free article] [PubMed] [Cross Ref]

25. Sepkovic DW, Raucci L, Stein J, Carlisle AD, Auborn K, Ksieski HB, et al. 3,3′-Diindolylmethane increases serum interferon-γ levels in the K14-HPV16 transgenic mouse model for cervical cancer. In Vivo. 2012;26(2):207–211. [PubMed]

26. Sepkovic DW, Pagan DV, Stein J, Carlisle AD, Ksieski HB, Auborn K, et al. Evaluation of 3,3′-diindolylmethane with gardasil quadrivalent HPV vaccine in K14-HPV16-transgenic mice cervical histology. In Vivo. 2013;27(3):299–304. [PubMed]

27. Ge X, Yanni S, Rennert G, Gruener N, Fares FA. 3,3'-Diindolylmethane induces apoptosis in human cancer cells. Biochem Biophys Res Commun. 1996;228(1):153–158. doi: 10.1006/bbrc.1996.1631. [PubMed] [Cross Ref]

28. Chen DZ, Qi M, Auborn KJ, Carter TH. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J Nutr. 2001;131(12):3294–302. [PubMed]

29. Semov A, Iourtchenko L, Liu LF, Li S, Xu Y, Su X, et al. Diindolylmethane (DIM) selectively inhibits cancer stem cells. Biochem Biophys Res Commun. 2012;424(1):45–51. doi: 10.1016/j.bbrc.2012.06.062. [PubMed] [Cross Ref]

30. Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E. 3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol. 2012;263(3):345–51. doi: 10.1016/j.taap.2012.07.007. [PMC free article] [PubMed] [Cross Ref]

31. Wu TY, Khor TO, Su ZY, Saw CL, Shu L, Cheung KL, et al. Epigenetic modifications of Nrf2 by 3,3'-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors. AAPS J. 2013;15(3):864–74. doi: 10.1208/s12248-013-9493-3. [PMC free article] [PubMed] [Cross Ref]

32. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6(2):65–70.

33. Meyskens FL, Jr, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoicacid: a randomized trial. J Natl Cancer Inst. 1994;86:539–43. doi: 10.1093/jnci/86.7.539. [PubMed] [Cross Ref]

34. Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, et al. Effects of β-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol. 1997;65:483–92. doi: 10.1006/gyno.1997.4697. [PubMed] [Cross Ref]

35. Butterworth CE, Jr, Hatch KD, Soong SJ, Cole P, Tamura T, Sauberlich HE, et al. Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol. 1992;166:803–9. doi: 10.1016/0002-9378(92)91337-A. [PubMed] [Cross Ref]

36. Grech G, Zhan X, Yoo B, Bubnov R, Hagan S, Danesi R, et al. EPMA position paper in cancer: current overview and future perspectives. EPMA J. 2015;6:9. doi: 10.1186/s13167-015-0030-6. [PMC free article] [PubMed] [Cross Ref]

37. Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol. 2010;116(3):464–7. doi: 10.1016/j.ygyno.2009.10.060. [PubMed] [Cross Ref]

38. Zeligs MA, Sepkovic DW, Manrique C, Macsalka M, Williams DE, Bradlow HL. Absorption-enhanced 3,3'-diindolylmethane: human use in HPV-related, benign and pre-cancerous conditions. Proc Am Assoc Cancer Res. 2002;43:Abs. 3198.

39. Castañon A, Tristram A, Mesher D, Powell N, Beer H, Ashman S, et al. Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer. 2012;106(1):45–52. doi: 10.1038/bjc.2011.496. [PMC free article] [PubMed] [Cross Ref]

40. Zhu J, Li Y, Guan C, Chen Z. Anti-proliferative and pro-apoptotic effects of 3,3′-diindolylmethane in human cervical cancer cells. Oncol Rep. 2012;28(3):1063–8. [PubMed]

41. Carter TH, Liu K, Ralph W, Chen D, Qi M, Fan S, et al. Diindolylmethane alters gene expression in human keratinocytes in vitro. J Nutr. 2002;132(11):3314–3324. [PubMed]

42. Savino JA, Evans JF, Rabinowitz D. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol Cancer Ther. 2006;5(3):556–63. doi: 10.1158/1535-7163.MCT-05-0355. [PubMed] [Cross Ref]

43. Golubnitschaja O, Costigliola V, EPMA General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14. doi: 10.1186/1878-5085-3-14. [PMC free article] [PubMed] [Cross Ref]

Articles from The EPMA Journal are provided here courtesy of Springer